Merus

$20.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.28 (-1.35%) Today
$0.00 (0.00%) As of 11:22 AM UTC after-hours

Why Robinhood?

You can buy or sell Merus and other stocks, options, and ETFs commission-free!

About MRUS

Merus N.V. Common Shares, also called Merus, is a clinical-stage immune-oncology company, which engages in the discovery and development of bi-specific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands. The listed name for MRUS is Merus N.V. Common Shares.

CEO
Sven Ante Lundberg
Employees
—
Headquarters
Utrecht, Utrecht
Founded
2003
Market Cap
800.24M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
149.80K
High Today
$21.48
Low Today
$19.35
Open Price
$20.98
Volume
121.02K
52 Week High
$31.27
52 Week Low
$10.18

MRUS Earnings

-$1.15
-$0.77
-$0.38
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 11, After Hours

You May Also Like

AMEH
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure